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introduction: Change in migraine headache (MH)—preexisting MH change or devel-
opment of de novo MH—are known potential complications following percutaneous 
closure of atrial septal defect (ASD), but consensus on a causal trigger remains elusive.
Objectives: To expose potential MH triggers linked, mainly by timing and occurrence, to 
the emergence of de novo MH or change in preexisting MH subsequent to percutaneous 
ASD closure (pASDC).
Methods: The literature was systematically searched for studies available in English 
reporting MH status after pASDC published between January 1, 1990 and November 
15, 2015. We determined the number and percentage of patients experiencing MH 
status change within 7 days post procedure and the cumulative total by final follow-up 
(Mdn = 12 months).
Results: Twenty-five studies met the inclusion criteria, which accounted for a total of 
1,646 pASDC patients. Pre-procedure MH prevalence was 8% (126/1,646). Change 
in preexisting MH occurred in a total of 72% (91/126), 12% (11/91) within 7-days after 
pASDC; within follow-up MH improved in 14% (18/126), resolved in 37% (47/126), but 
persisted in 63% (79/126). De novo MH incidence ranged between 10 (153/1,520) 
and 18.3% (153/836); 34% incipience (52/153) was within 7-days of pASDC; females 
accounted for 80% (63/79) of gender differentiated cases; of type distinguished cases, 
42% (51/122) were MH without aura (MO) and 58% (71/122) were MH with aura (MA); 
MH improved in 10% (16/153), resolved in 24% (37/153) but persisted beyond final 
follow-up in 76% (116/153). Antiplatelet agents were effective modulators of MH in 44% 
(11/25) studies. Possible adverse MH-predisposing traits were scarce: larger ASD size 
reported in ~2% (39/1,646) of patients experiencing de novo MH or preexisting MH 
exacerbation; short aortic rim reported in three de novo MH patients; allergic response 
to occluder nickel alloy in four patients with MH status change from baseline (de novo or 
preexisting MH change not specified).
Abbreviations: ASD, atrial septal defect; IHS, International Headache Society; MH, migraine headache; MA, migraine with 
aura; MO, migraine without aura pASDC, percutaneous atrial septal defect closure; PFO, patent foramen ovale.
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iNTRODUCTiON
Migraine pathogenesis is a contentious, unresolved issue with 
rival theories implicating various neurovascular and biochemical 
mechanisms. Research has revealed a 3–5  mm/min propagat-
ing wave of depolarization referred to as cortical spreading 
depression (SD) or simply SD—neuronal excitation followed by 
depression—as a demonstrated substrate of migraine with aura 
(1–3) that is associated with initial hypoperfusion followed by 
hyperemia (4). SD has been linked to trigeminal system activa-
tion (3, 5–8), which is involved in pain transmission.
In a much simplified description of the trigeminal pain path-
way [for an elaboration, see Noseda and Burstein (9)], trigeminal 
axons projecting from the meninges and associated blood vessel 
nociceptors (the peripheral trigeminovascular system) carry pain 
signals to the brainstem trigeminocervical complex comprised of 
the caudal trigeminal nucleus and spinal cord dorsal horns C1 
and C2. Projections from this complex ascend and connect with 
other brainstem nuclei (e.g., the ventrolateral periaqueductal 
gray) before connecting with the more dorsal hypothalamic and 
thalamic nuclei. Since the caudal trigeminal nucleus and thalamic 
nuclei [with respect to the thalamus, principally, in migraine, 
the ventral posteromedial nucleus (VPM)] are central nervous 
system structures that advance processing of peripheral (trigemi-
novascular system) input they are referred to as the central 
trigeminovascular system. The VPM is a particularly important 
sensory relay for the face and head. The VPM thalamic nuclei 
project, in somatotopic fashion, to the primary and secondary 
somatosensory cortices (and to the insula). Efferent fibers from 
the VPM, for example, project to the face area of the primary 
somatosensory cortex (9, 10).
The trigeminal nerve ganglion and nerve endings release 
vasoactive neuropeptides into meningeal nociceptors; notably, 
substance P, serotonin, and calcitonin gene-related peptide 
(CGRP) (11, 12). A biochemical theory of migraine implicates 
vasoactive substances in migraine, such as 5-hydroxytryptamine 
(serotonin), and there is evidence that serotonin metabolism is 
impaired in migraineurs (13) and that serotonin released from 
aggregating platelets may be involved in the vasoconstriction and 
vasodilation associated with migraine headache (MH) (14). In 
addition, research implicates altered platelet activity in migraine 
(14–20).
Agreement on the SD trigger mechanism remains elusive. 
Genetic predisposition is a likely factor (21) but other variables 
are also in play. The phenomenon of SD has been induced by 
a variety of stimuli: introduction of tetanic electrical impulses, 
chemical agents, such as potassium ions (22) and glutamate, as 
well as hypoxia (23). Transient tissue oxidation has evoked SD 
in rats (5) and more recent data has intriguingly shown induced 
SD in mice from introduced microemboli with apparent associ-
ated hypoperfusion but without imaging (9.4T) or histological 
evidence of tissue infarct (17). Contrarily, dampened SD has 
been reported in rats through administration of CGRP-receptor 
antagonists (22).
Although the mechanism initiating the cascade of events 
involved in migraine is yet to be confirmed, migraine pain man-
agement has been advanced through intensified CGRP research. 
The neuropeptide CGRP is found in 50% of trigeminal neurons 
and in all organ systems of the body (10). There is a well-doc-
umented linkage between CGRP release and migraine (24–27), 
and GGRP has proven to be a factor in vasodilation of meningeal 
vessels (28, 29). The neuropeptide exhibits heightened levels dur-
ing MH attack (29), its intravenous introduction can induce MH 
interictally in MA patients (30) and triptans (e.g., sumatriptan) 
diminish release of CGRP and are relatively effective in manage-
ment of migraine pain (31). CGRP-receptor antagonists as well as 
monoclonal antibodies show promise for the future of MH pain 
management (32, 33).
For MA, here is a known association between cardiovascular 
risk factors such as pre-clinical brain lesions and ischemic stroke 
(34–39), which implicates inflammatory response as a potential 
trigger of SD, at least as concerns MA. Experimental hypoxia has 
been demonstrated to induce aura or migraine-like symptoms in 
migraine patients and induce migraine aura-like symptoms in 
healthy controls (40). In recent onset migraineurs, altered arterial 
measures have been documented, including reduced brachial and 
femoral artery compliance as well as decreased brachial artery 
diameter (41). Elevated vascular risk factors have been found in 
migraineurs, including vasoactive plasma endothelin (ET-1), a 
marker for atherosclerosis and endothelia injury (42). Increased 
carotid artery media thickness, a subclinical marker of early ath-
erosclerosis (43, 44), has been reported as heightened in pediatric 
migraineurs (45) and in adult migraineurs (42).
Within the clinical context of corrective heart procedures, 
a procedure specific vascular-related trigger to MH surfaced 
when a multivariate analysis found one such type of corrective 
procedure was the only independent predictor of de novo MH 
onset (46). In brief, the corrective procedure in general involves 
non-surgical repair of an atrial septal defect (ASD). An ASD is a 
deficit in the interatrial septum resulting in a gap or hole between 
the right and left atria enabling abnormal interatrial blood flow 
and mixing of right atrial venous and left atrial arterial blood. 
The corrective procedure is referred to as percutaneous (or 
transcatheter) ASD closure (pASDC) and involves imaging 
guidance [typically transesophageal echocardiography (TEE)] 
of a catheter inserted in the femoral vein and directed to the 
interpretation: Early intensification of MH status change but later amelioration (virtually 
paralleling stages of endothelialization), relatively high efficacy of antiplatelet agents, and 
the emergence of MA as the dominant de novo MH type favor proinflammatory triggers 
of MH status change after pASDC.
Keywords: atrial septal defect closure, migraine, percutaneous closure, transcatheter closure, de novo migraine
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interatrial septum. The catheter has an attached occluder device 
that is maneuvered to plug the interatrial hole. Once the occluder 
is deemed securely and correctly positioned, the catheter is with-
drawn (47). Patients are typically started on antithrombotic 24 h 
before the procedure and continue antithrombotic therapy for 
3–6 months after the procedure. The percutaneous ASD closure 
(pASDC) method of treatment has a track record of positive 
cardiac remodeling and high safety and efficacy (48–51) as well 
as high rates of closure success including a long-term closure rate 
verification of 97% (52). ASD prevalence is 1–3 in 10,000 and is 
more common in females than males, with a female to male ASD 
ratio of 1.6 (53). Migraine prevalence is also higher in women, 
about three times higher, with the peak incidence between 25 
and 55 years of age (54).
Change in preexisting MH (exacerbation, improvement, 
complete resolution) or development of de novo MH, are broadly 
acknowledged neurological alterations that can follow pASDC. 
However, the prevalence in patient frequency of MH change 
within days to months after pASDC has not been formally 
reviewed across studies.
This review focuses on migraine, its de novo appearance or 
modulation, in the context of the corrective coronary procedure 
pASDC. The objective was to shed further light on potential MH 
triggers by examining qualitative data (patient frequency and 
percentage) from the literature to assess the influence of pASDC 
and other pertinent clinical (e.g., effectiveness of antiplatelet 
agents) and demographic data on change in MH status. Of par-
ticular interest was the proportion of patients who experienced 
de novo MH onset within 7  days from pASDC. New onset of 
MH occurrence constrained within this short time interval has 
minimized likelihood of procedure-extraneous confounds and 
provides a unique window to the pathogenesis of migraine, at 
least as it occurs within this context. Procedure-related events 
(e.g., proinflammatory response factors) loom large as potential 
MH triggers. In addition, the proportion of patients in whom MH 
resolved within follow-up (median of 12 months) or persisted after 
follow-up was also determined as these are variables that further 
characterize migraine and its potential underlying mechanisms. 
Such time-to-event measures provide an indication of the extent 
to which stages of healing, notably endothelialization, parallel 
and potentially contribute to MH status change. Additional 
differentiation of MH status change after pASDC by gender and 
type was also extracted from the data, but it was restricted in the 
literature, and consequently in this review, to subsets of de novo 
MH patients. Finally, an overview was included of biochemical, 
microembolic, and allergy factors ostensibly informing on MH.
MeTHODS
Literature Search
There is no prior protocol for the current review. Cochrane 
databases, Google Scholar, PubMed, and Web of Science were 
systematically searched for relevant primary clinical observa-
tion and research data published between January 1990 and 
December 2015. The search arguments used were ((atrial septal 
defect) in Title)) and ((migraine) in Title), ((percutaneous) in 
Title) and ((atrial septal defect) in Title) and ((migraine) in Title), 
((transcatheter) in Title) and ((atrial septal defect) in Title) and 
((migraine) in Title), ((atrial septal defect) in Title) and ((closure) 
in Title), ((atrial septal defects) in Title) and ((migraine) in Title), 
((atrial septal defects) in Title) and ((headache) in Title), ((atrial 
septal defect) in Title) and ((headache) in Title), ((interatrial 
shunts) in Title) and ((migraine) in Title), ((percutaneous) in 
Title) and ((atrial septal defect) in Title) and ((migraine) in any 
field, ((atrial septal defects) in Title) and ((transcatheter) in Title) 
and ((migraine) in any field). For background information, the 
literature was also searched for ((patent foramen ovale) in Title) 
and ((migraine) in Title) as well as for migraine theories. To 
provide background on migraine in general, migraine not associ-
ated with pASDC, additional data were retrieved from Google 
Scholar, PubMed, and Web of Science for migraine pathogenesis 
and management in general with search arguments including 
((migraine) in Title) and ((pathogenesis) in Title) as well as 
((migraine) in Title) and ((management) in Title).
Study Selection and inclusion Criteria
This review sought evidence linking pASDC and migraine status 
change: change after pASDC in status of preexisting MH as well as 
the occurrence of de novo MH inception. Preexisting MH status 
change was defined mainly as change in frequency or severity or 
MH type. Study screening and inclusion criteria were as follows: 
(1) assessment of potential migraine status change—alteration 
of prior MH or de novo MH—after pASDC; (2) diagnosis of 
migraine by qualified personnel (i.e., neurologist, cardiologist), 
and preferably employing International Headache Society (IHS) 
migraine criteria (55, 56); (3) an English language version of the 
report; (4) data sufficiently explicit and complete for qualitative 
data review. With respect to point (2), absence of IHS criteria 
did not exclude a report from inclusion. As regards point (4), 
this was a qualitative review simply because there was insufficient 
appropriate quantitative data across studies for analysis of MH 
status change after pASDC.
Measures
The number (patient count) and percentage of patients experi-
encing MH status change after pASDC was calculated for pre-
existing and de novo MH patient categories, but more data were 
available for de novo MH. Specifically, data differentiating MH 
status change by gender and type after pASDC was only available 
for de novo MH. Change in preexisting MH status after pASDC 
differentiated by gender or type was too scarcely reported to 
include as a review-wide representative measure. The categories 
of qualitative data available for change in preexisting MH were 
pre-procedure MH type (MO and MA), change in preexisting 
MH within 7 days after pASDC, change in preexisting MH by 
final follow-up months later, and improvement or resolution in 
preexisting MH by final follow-up. With the exception of pre-
procedure MH type, de novo MH data categories were the same 
but de novo MH was additionally differentiated by MH type and 
gender, though such differentiation was not consistent across all 
studies. De novo MH incipience within 7 days from pASDC dif-
ferentiated by type was also recorded. All categories are listed in 
Table 1. The effect of pASDC on MH change was also informed 
TAbLe 1 | (A): prevalence of PeMH change (preexisting MH change: change in frequency, severity or type of migraine) after pASDC in patients with a 
history of MH; (b): prevalence de novo MH after pASDC.
Number of studies Percentage fractions n/n %
(A) Preexisting MH category
PEMH Hx 12 PEMH Hx/Grand N 126/1,646 8
PEMH MO 7 PEMH MO/PEMH Hx 55/126 44
PEMH MA 9 PEMH MA/PEMH Hx 46/126 37
PEMH CHG 12 PEMH CHG/PEMH Hx 91/126 72
PEMH CHG Wi 7d from pASDCa 6 PEMH CHG Wi 7d/PEMH CHG 11/91 12
PEMH Impr Wi FUP 6 PEMH Impr Wi FUP/PEMH Hx 18/126 14
PEMH Res Wi FUP 9 PEMH Res Wi FU/PEMH Hx 47/126 37
(b) De novo MH category
De novo MH 18 De novo MH/Grand N 153/1,646 9
De novo MOb 8 De novo MO/De novo MH 51/122 42
De novo MAb 12 De novo MA/De novo MH 71/122 58
De novo MH Wi 7d from pASDC 11 De novo MH Wi 7d/De novo MH 52/153 34
De novo MO Wi 7d from pASDC 3 De novo MO Wi 7d/De novo MH Wi 7d 6/52 12
De novo MA Wi 7d from pASDC 8 De novo MA Wi 7d/De novo MH 7d 25/52 48
De novo MH Fc 11 De novo MH F/De novo MH 63/79 80
De novo MH Mc 7 De novo MH M/De novo MH 16/79 20
De novo MH Impr Wi FUP 2 De novo MH Impr Wi FUP/ 16/153 10
De novo MH
De novo MH Res Wi FUP 10 De novo MH Res Wi FUP/ 37/153 24
De novo MH
aThere were 12 studies indicating PEMH CHG, but only 6 specified migraine headache (MH) change within 7 days from percutaneous ASD closure (pASDC).
bType of migraine was not differentiated in 31 patients across 7 studies.
cIn 74/153 patients (48%), gender of those presenting with de novo MH was not specified.
De novo MH, new-onset migraine; Grand N, total across patient number (1,646); F, female; M, male; MA, migraine with aura; Impr, improved; MH, migraine headache; MH Hx, 
migraine history; Impr, improvement; MO, migraine without aura; n, patient count; Nbr, number; Pat, patient; pASDC, percutaneous atrial septal defect closure; PEMH, preexisting 
MH; Res, resolved; Wi, within; 7d, 7 days.
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by individual study characterizations of MH change. Additional 
data items extracted where possible were mean age, mean follow-
up (months), gender ratio (female to male), antiplatelet agents, 
rate of successful ASD closure, occluder device type used, and use 
of IHS migraine diagnostic criteria (see Table 3).
Qualitative Data Analysis
Qualitative findings were expressed in frequencies (number of 
patients falling into the aforementioned categories) and percent-
ages. Values represent the number of patients not the number of 
episodes. Data were tabulated and graphed where appropriate. 
A frequency distribution of the variables of primary interest 
noted in the previous section was also calculated (Table S1 in 
Supplementary Material). Data analysis was completed in R ver-
sion 3.2.4.
ReSULTS
A total of 60 studies were returned by a search of Cochrane 
databases, Google Scholar and PubMed. After removing dupli-
cates, there were 34 articles. Of the 34 articles, one study was 
not included because it could not be accessed (86) at the time 
of this writing. Two of the articles were not included because 
they did not report on MH in the context of ASD (74, 87); these 
two articles were used for additional background information. 
Three additional articles were not included because, although 
relevant, at the time of this review they were not available in 
English (88, 89). Two of the articles were commentaries (90, 91) 
and discarded. There were 25 articles remaining that adequately 
fulfilled the inclusion criteria.
Prevalence of Migraine after Percutaneous 
ASD Closure
Twenty-five articles based on original research represented the 
prevalence of migraine and accounted for 1,646 patients who 
underwent pASDC. After pASDC, patients experiencing change 
in preexisting MH was reported in 12 of 25 studies and those 
experiencing de novo MH was reported in 18 of 25 studies; 7 stud-
ies reported patients with both change in preexisting MH and de 
novo MH (19, 52, 61, 64, 71, 76, 81). In terms of study type, change 
in preexisting MH was reported in 3 of 8 case studies (62, 70, 82); 
2 of 3 prospective studies (71, 84), and in 9 of 13 retrospective 
studies (19, 52, 59–61, 63, 64, 76, 81). De novo MH was reported 
in 5 of 8 case studies (57, 73, 75, 78, 92), in 2 of 3 prospective stud-
ies (71, 72), and in 11 of 13 retrospective studies (19, 46, 51, 52, 
58, 61, 64, 67, 77, 81, 93). Finally, a recent randomized controlled 
trial reported de novo MH following pASDC (79).
Overall, de novo MH data were more frequently (and explicitly) 
reported than change in preexisting MH data. This is conveyed by 
a visual inspection of Figure 1. The circles in Figure 1 are scaled 
to reflect individual study sample size (n) on the y-axes and the 
x-axes indicate patient count. The left graph (Figure 1A) reflects 
the sample size and number of patients in whom change in 
preexisting MH differed (in frequency or severity) from baseline 
MH and the right graph (Figure 1B) reflects the sample size and 
number of patients in whom de novo MH occurred. Clearly, there 
are more studies reporting zero change in patients (on the x-axis) 
5Leger and DeSouza Migraine Modulation and Debut
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with preexisting MH in Figure  1 relative to studies reporting 
zero de novo MH illustrating that there was more de novo MH 
data available for this review. The circles in Figure 1 also convey 
a measure of distribution consistency among studies reporting 
change in MH status, as larger studies tend to show higher counts 
of change in preexisting MH or de novo MH.
Where provided by the literature, relevant continuous data 
with significant results are highlighted in this review on a 
study-by-study basis (see Results subsection Study Highlights). 
A summary of findings for change in preexisting MH will be 
reviewed first followed by a summary of findings for de novo MH 
occurrence (see Frequencies and Percentages). This will be fol-
lowed by précises of relevant individual study highlights arranged 
by category (preexisting MH or de novo MH) and study-type: 
case, prospective, retrospective, and a single random controlled 
trial (RCT).
Frequencies and Percentages
Table 1 summarizes overall MH prevalence; frequencies and per-
centages are based on the number of patients in a given category. 
Table 2 provides individual study details of the patient count and 
percentage in categories arguably most demonstrative of potential 
change in MH status after pASDC. Frequency distributions are 
provided in Table S1 in Supplementary Material. Note, to reduce 
the size of Table 2, six after pASDC measures were omitted: the 
breakdown of de novo MH patient number by gender, number 
of patients with prior MH who experienced improvement, the 
number of de novo MH patients who experienced improvement, 
the number of de novo MO, and MA patients who experienced 
de novo MH within 7 days from pASDC. However, these data can 
be derived from Table S1 in Supplementary Material. Also in aid 
of reducing table size, the breakdown of pre-procedure MH by 
type in those with preexisting MH was omitted in Table 2 and 
Table S1 in Supplementary Material, but these data are available 
upon request.
Recall, as specified in Section “Methods” (see Measures), two 
time points were set from which patient count of change in MH 
status was derived: the frequency of patients experiencing change 
in MH status within 7 days from pASDC and the total cumulative 
number at final follow-up. Patient count of MH status change at 
these two time points is represented in Figure 2. Figure 2 y-axes 
reflect patient count of MH status change after pASDC; the 
numbers in Figure 2 x-axes represent the study that corresponds 
to a given bar; corresponding studies are listed sequentially in 
Table  2. In the left side graphs of Figure  2, panel (A) depicts 
patient count of MH change within 7 days from closure in patients 
with preexisting MH; panel (C) depicts the patient count of MH 
change cumulatively by final follow-up in those with preexisting 
MH. On the right side of Figure 2, panel (B) depicts patient count 
of de novo MH within 7 days from closure, and panel (D) depicts 
the cumulative patient count of de novo MH by final follow-up.
Of the 1,646 patients, 126/1,646 (8%) had a history of MH 
prior to pASDC. There were 55/126 patients with MO (44%) and 
46/126 patients (37%) with MA. Type of MH was not differenti-
ated in 25/126 patients (20%) with a prior history of MH. Change 
in preexisting MH occurred in 91/126 patients (72%) with a prior 
history of MH after pASDC. These 91 patients constituted the 
preexisting MH change group in whom change in MH status 
occurred within follow-up. As noted in Section “Methods,” break-
down of post pASDC change in preexisting MH either by gender 
or MH type was not available across studies. For patients with a 
prior history of MH, change in preexisting MH occurred in 11/91 
patients (12%) within 7 days after pASDC and the remaining 80 
patients experienced MH change within follow-up. Preexisting 
MH improved in 18/126 (14%) within follow-up and resolved in 
47/126 patients (37%) within follow-up.
De novo MH occurred in 153/1,646 patients (9%). The pro-
portion of de novo MH relative to those with no prior history of 
migraine ranged between two percentages. While 836 patients 
were specified as without any prior MH history, there were also 
684 patients in whom MH history status was not explicitly speci-
fied. The proportion of de novo MH in those with no prior MH 
history lies between a lower estimate of 153/1,520 (10%) and 
a higher estimate of 153/836 (18%). Within 7  days of pASDC, 
de novo MH onset occurred in 52/153 patients (34%), and the 
remaining 101/153 patients (66%) with de novo MH accrued 
within follow-up. The type of de novo MH was not distinguished 
in seven studies, which collectively accounted for 31/153 patients 
(20%). In the 122 cases where MH type was differentiated, de novo 
MO incipience occurred in 51/122 patients (42%) and de novo MA 
incipience occurred in 71/122 patients (58%). De novo MO within 
7  days from pASDC accounted for MH debut in 6/52 patients 
(12%) and de novo MA within 7 days from pASDC accounted 
for MH debut in 25/52 patients (48%). De novo improvement but 
not complete resolution occurred in 16/153 patients (10%) and 
MH resolution occurred in 37/153 de novo MH patients (24%) 
within follow-up.
In those patients with a prior history of MH in whom MH 
persisted at final follow-up, data indicated significant reductions 
in episode frequency or severity (59, 61, 71, 81) or a course of 
gradual decreased frequency and overall improvement (19, 62, 
76, 84). Nevertheless, preexisting MH persisted beyond final 
follow-up in 79/126 (63%) of patients with a prior history of MH. 
Similarly, in de novo MH patients, indications were for significant 
reduction (81) or a course of gradual decreased frequency and 
general improvement (46, 72, 76, 81), but MH persisted beyond 
final follow-up in 116/153 (76%) patients. Instances of de novo 
MH perpetuating beyond 2 years [(78): three pediatric patients], 
5 years [(58): one pediatric patient], and 7 years [(73): one adult] 
were reported.
Eight of 25 studies included pediatric patients (46, 51, 52, 58, 
76, 78, 92, 93). Occurrence of de novo MH has been reported 
to not differ significantly between pediatric and adult patients 
(51) (Vijarnsorn Beneficial 2012), though, antithetically, other 
research reports higher de novo MH prevalence among pediatric 
patients (46, 76) and younger adult patients (46, 61). Some data 
indicated adults who underwent change in preexisting MH were 
younger that those in whom MH did not persist or develop (61).
As concerns other data not tabulated in this review but 
potentially germane to MH status, ASD clinical characteristics 
[pulmonary-to-systemic flow ratio (Qp/Qs), ASD size, occluder 
size, etc.] generally did not differ significantly between those who 
did and those who did not experience pASDC migraine status 
change—change in preexisting MH or de novo MH. However, 
TAbLe 2 | Migraine prevalence: individual study details.
Reference Study type Study n PeMH MH 
Hx: n (%) of 
study n
PeMH MH 
CHG: n (%) of 
PeMH MH
PeMH MH 
CHG wi 7d. 
pASDC: n (%) 
of Per MH 
CHG
PeMH MH 
resolved wi 
FUP: n (%) of 
PeMH MH
De novo MH: n 
(%) of study n
De novo MO: 
n (%) of de 
novo MH
De novo MA: 
n (%) of de 
novo MH
De novo 
MH wi 7d 
pASDC: n 
(%) of de 
novo MH
De novo MH 
resolved wi 
FUP: n (%) of 
de novo MH
Yankovsky and Kuritzky (13) Case 1 1 (100) 1 (100) 1 (100) 1 (100) 0 0 0 – –
Rodes-Cabau et al. (57) Case 1 0 0 – – 1 (100) 0 1 (100) 1 (100) 1 (100)
Yew and Wilson (58) Retro 25 – – – – 2 (8.0) – – 1(50.0) 1 (50.0)
Wilmshurst et al. (19) Retro 71 21 (29.6) 21 (100) – – 9 (12.7) 7 (77.8) 2 (22.2) – –
Azarbal et al. (59) Retro 23 7 (30.4) 4 (57.1) – 3 (42.9) 0 0 0 – –
Kedhi and Vermeersch (60) Retro 14 – – – – 0 – – – –
Mortelmans et al. (61) Retro 75 22 (29.3) 12 (54.5) – 12 (54.5) 10 (13.3) 3 (30) 7 (70.0) – 6c (60.0)
Riederer et al. (62) Case 1 1 (100) 1 (100) 1 (100) 3 0 0 0 – –
Sharifi et al. (63) Retro 13 5 (38.5) 5 (100) 5 (100) 5 (100) 0 0 0 – –
Wertman et al. (64)a Retro 42 2 (4.8) 2 (100) – – 2 (4.8) – – – –
Fernández-Mayoralas et al. (65) Case 97 0 0 – – 4 (4.1) 0 4 (100) 4 (100) 4 (100)
Li (66) Retro 188 0 0 – – 3 (1.6) – NA 2 (66.7) 3 (100)
Providencia et al. (67, 68) Retro 25 0 0 – – 3 (12.0) – NA – 2 (66.7)
Rodés-Cabau (46, 69) Retro 112 0 0 – – 13 (11.6) 4 (30.8) 9 (69.2) 6 (46.2) 4 (30.8)
Castellini et al. (70) Case 3 3 (100) 3 (100) 1 (33.3) 2 (66.7) 0 0 0 – –
Luermans et al. (71) Pros 63 23 (36.5) 15 (60.9) – 13e (56.5) 4 (6.3) 2 (50.0) 2 (50.0) 4 (100) –
Knepp et al. (52) Retro 94 2 (2.1) 2 (100) – 2 (100) 4 (4.3) – NA – –
Riederer et al. (62) Pros 22 10 (59.1) 7 (70.0) 1 (14.3) 3 (30.0) 0 0 0 0 –
Wei et al. (72) Pros 40 0 – – – 24 (60.0) 11 (45.8) 13 (54.2) – 7 (29.2)
Benemei et al. (73) Case 1 0 0 – – 1 (100) 0 1 (100) 1 (100) 0
Vijarnsorn et al. (51, 74) Retro 353 – – – – 19 (5.4) – NA – –
Kato et al. (75) Case 1 0 0 – – 1 (100) 0 1 (100) 1 (100) 1d (100)
Kato et al. (76, 77) Retro 207 29 (14.0) 18 (62.1) 2 (11.1) 6 (20.7) 23 (11.1) 10 (43.5) 13 (56.5) 13 (56.5) 8 (34.8)
Armstrong et al. (78) Case 3b 0 0 – – 3 (100) 1 (33.3) 2 (66.7) 3 (100) 0
Rodés-Cabau (79, 80) Random 
controlled trial
171 0 0 – – 27 (15.8) 13 (48.1) 14 (51.9) 16 (59.3) –
Totals 1,646 126 91 11 47 153 51 71 52 37
The first author is italicized in studies including pediatric patients.
The n (%) values are individual study patient number and percentages within the specified categories. Percentages reflect a given category’s proportion of patients from that study’s total number of patients.
aAfter closure, five patients were reported with either exacerbated MH or de novo MH, but the breakdown was not specified. To reduce bias, an equal number of two patients were allocated to each category (PEMH MH CHG, which 
includes exacerbation and improvement, and de novo MH).
bWhile there was a total of four patients, three patients had percutaneous ASD closure and one underwent surgical closure.
cLater follow-up was provided by another study from the same camp (81) monitoring the same patients.
dWhile MH resolved aura persisted.
eThis percentage is likely imprecise as MH status of ~5 of the original 23 patients was unknown at final follow-up.
The dash (–), data not available or not applicable; CHG, change; De novo MH, new-onset migraine; FUP, follow-up; Hx, history; MA, migraine with aura; MH, migraine headache; MH, migraine headache; MO, migraine without aura; 
pASDC, percutaneous atrial septal defect closure; PEMH, preexiting MH; Pros, prospective; Retro, retrospective; Wi, within; 7d, 7-days.
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FiGURe 1 | The y-axes reflect study sample size; the x-axes show patient count (the number of patients) of those who experienced migraine 
headache (MH) status change after pASDC. Some studies reported similar incidence of MH status change and to limit overplotting of duplicate patient counts 
the data were jittered.
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Wei et  al. (72) reported significantly larger ASD size and ASD 
length to occluder length ratio in de novo MH patients, and 
Mortelmans et al. (61) reported significantly larger ASD size in de 
novo patients (and in patients with preexisting MH change after 
pASDC). There was a 93% rate of successful ASD closure within 
follow-up, and major adverse events were rare. Adverse events 
were defined as evidence within follow-up of device thrombus 
formation, embolism, requirement of cardiac surgical interven-
tion (perhaps due to occluder migration), pericardial effusion, 
stroke, or death. Evidence of device thrombus formation was 
reported in just two studies (52, 93), involved two patients, one 
from each study: within 10 days, one patient’s thrombus disap-
peared with intensified administration of anticoagulant; the other 
patient was a 25-month-old infant with a large ASD and a res-
piratory comorbidity, and this patient expired. In three patients, 
device migration occurred requiring surgical explantation (93).
Individual study demographic and clinical characteristics 
are shown in Table 3 and include mean age (which varied con-
siderably given inclusion of adult and pediatric patients), mean 
follow-up time (months); female to male ratio, antithrombotics, 
percentage of Amplatzer occluder devices used, percentage of 
successful pASDC, and the MH diagnostic reference used. Mean 
follow-up time ranged from 3 to 73  months (Mdn =  12). The 
female to male ratio of pASDC patients was 1,263/533 (2.37). 
Unfortunately, change in preexisting MH differentiated by gender 
was too inconsistently documented to determine proportionate 
MH change after pASDC by gender in those with a prior history 
of MH. With respect to de novo MH patients, new-onset MH was 
differentiated by gender in 79/153 de novo patients (52%): females 
accounted for 63 and males 16 of the de novo MH patients, 
which means a percentage difference of 80% (63/79) de novo 
MH occurred in females and 20% (16/79) in males. In 74/153 
patients (48%) with de novo MH, gender of patients with MH 
debut was not specified. Effective modulation of MH status by 
antithrombotics was expressly reported in 11/25 or 44% of studies 
(19, 57, 63, 64, 70, 72, 73, 76, 78, 79, 82). Acetylsalicylic acid 
(ASA) was used in 21/25 (84%) studies, and the thienopyridine 
clopidogrel was used in conjunction with ASA in 12/25 (48%) of 
studies. The IHS criteria for migraine assessment was adopted 
in 17/25 (68%) studies and the Amplatzer™ septal occluder was 
used in 95.5% of patients; note, in the highlights that follow, use 
of IHS criteria and Amplatzer™ occluder devices in a given study 
should be assumed unless otherwise stipulated. Further, and as 
concerns the highlights that follow, demographic and clinical 
characteristics from Table 3 are not reiterated unless, according 
to a given study, they lent purported weight to the main outcome 
measure of migraine status change after pASDC.
Study Highlights
Preexisting Migraine Change after Percutaneous 
ASD Closure: Case Studies
Adult patients were involved in all three of the case studies report-
ing change in preexisting MH (62, 70, 82). Outcomes for all case 
study patients with preexisting MH were as follows: 3/5 patients 
(60%) across these case studies experienced change in preexisting 
MH within hours to 7 days after pASDC, and the remaining two 
patients experienced change in preexisting MH at 3 months post 
pASDC. After pASDC, transthoracic echocardiography (TTE) 
(or TEE) was normal (no evidence of embolization or thrombus) 
across patients but one patient’s MRI indicated periventricular 
lesions (62). Abnormal platelet activity was not reported for any 
patients, and all ASD shunts were resolved within follow-up peri-
ods. In three of the case study patients, the change in preexisting 
MH took the form of heightened MA attack frequency: from two 
to three times monthly to daily (82); from twice yearly to daily 
(62), and from once yearly to one to four times monthly [case 3 
(70)]. In four case study patients, pASDC attacks decreased in 
frequency (62) or remitted at final follow-up (70, 82); in one of the 
patients in which MO was transformed to MA after pASDC [case 
1 (70)], MA episodes were reported continuing with a frequency 
TAbLe 3 | Demographic and clinical characteristics.
Reference Study n Mean age 
(SD)
Mean 
FUP 
(mos)
Female:male 
ratio
Anti-thrombotic Successful 
ASD closure 
wi FUP %
Amplatzer 
ASO%
MH diagnostic 
reference
Yankovsky and Kuritzky (82) 1 48 6 0:1 Acetylsalicylic acid 
(ASA); PPL
100.0 100.0 –
Rodés-Cabau (57) 1 32 12 0:1 AMITRIP 100.0 100.0 International 
Headache Society 
(IHS)
Yew (83) 25 16 58 18:7 ASA 100.0 100.0 –
Wilmshurst et al. (19) 71 † 6 31:40 ASA, CLOP – 80.0 IHS
Azarbal et al. (59) 23 41 (15) 12 16:7 ASA, CLOP – 100.0 MIDAS
Kedhi and Vermeersch (60) 14 – NA NA – – – –
Mortelmans et al. (61) 75 51 (19) 29 59:16 – – 100.0 IHS
Riederer et al. (62) 1 27 3 1:0 ASA 100.0 100.0 IHS
Sharifi et al. (63) 13 32 (9) 9 9:4 ASA, CLOP – 100.0 IHS
Wertman et al. (64) 42 – – NA ASA, CLOP – 100.0 MIDAS
Fernández-Mayoralas et al. (65) 97 11.75 (5.31) 9 1:3 ASA, IBP 100.0 100.0 IHS
Li (66) 188 24.8 (17.9) 6 136:55 ASA 96.9 100.0 –
Providencia et al. (67, 68) 25 37.8 (17.7) 12 11:14 – – 100.0 IHS
Rodés-Cabau et al. (46, 69) 112 39 (19) 24 110:75 ASA, CLOP 100.0 100.0 IHS, MIDAS
Castellini et al. (70) 3 30.67 (11) 33 2:1 ASA, FNZ, LTG 100.0 100.0 IHS
Luermans et al. (71) 63 47.3 (16.4) 9 53:15 ASA, CLOP 96.3 91.2 IHS
Knepp et al. (52) 94 a 73 – ASA 97.0 100.0 –
Riederer et al. (84, 85) 22 50 (16) 12 16:9 ASA, CLOP, PPC 100.0 100.0 IHS
Wei et al. (72) 40 25.8 (2.4) 3 33:7 ASA, CLOP 90.0 100.0 IHS
Benemei et al. (73) 1 28 24 1:0 ASA, CLOP, TICLID 100.0 100.0 IHS
Vijarnsorn et al. (51, 74) 353 36b (13.23) 12 c ASA 98.8 100.0 –
Kato (75) 1 35 24 1:0 ASA, CLOP 100.0 100.0 IHS
Kato (76, 77) 207 27 41 146:61 ASA, CLOP TICLID 100.0 100.0 IHS
Armstronget al. (78) 3 8.5 (5.23) 24 2:1 ASA – 100.0 IHS
Rodés-Cabau (79, 80) 171 49 (15) 3 106:65 ASA, CLOP 99.4 100.0 IHS, MIDAS
The first author is italicized in studies including pediatric patients.
aTwo age groups, pediatric (n = 52): M = 7.5, SD = 4.6; adults (n = 42): M = 49.9, SD = 15.4.
bThere were three age groups: children < 18, adults 18–50, adults > 50.
cIn the original patient group there were 512 females and 153 males, but female to male breakdown in the final study group of 353 was not provided.
ASD, atrial septal defect; ASO, atrial septal occluder; FUP, follow-up; MH, migraine headache; mos, months; Antithrombotics: ASA, aspirin; AMITRIP, amitriptyline; CLOP, clopidogrel; 
FNZ, flunarizine; LTG, lamotrigina; PPC, phenprocoumon; PPL, propranolol; IBP, Ibuprofen; PIZ, Pizotofen; TPM, Topiramate; Ticlid, ticlopidine.
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of four episodes monthly at final follow-up (~33  months). 
Antiplatelet agents modulated MH change after pASDC (here, 
either increase in frequency or transformation of MO to MA) in 
a challenge–dechallege–rechallenge (CDR) pattern in two of case 
study patients [cases 1 and 3 (70)].
Preexisting Migraine Change after Percutaneous 
ASD Closure: Prospective Studies
Luermans et al. (71) reported a reduction in MH prevalence in 
23/68 patients (33.8%) with prior MH to a prevalence of 7/57 
(12.3%) 12 months after closure, which was a significant reduc-
tion (p  =  0.003). Change in preexisting MH occurred in 15 
patients: MH resolution occurred in 8/20 (40%) at 6 months and 
in an additional 5/18 (27.8) at 12 months after pASDC patients; 
MH changed from MA to MO in two patients (there were also 
four incidents of de novo MH: see the prospective section for de 
novo migraine prevalence after ASD closure). Riederer et al. (84) 
reported that of 22 pASDC patients, change in preexisting MH 
occurred in 7/22 (31.8%) within 6 months from pASDC: in three 
patients auras disappeared, attack frequency initially increased 
then decreased to or below baseline in three patients, and per-
sistent MH was resolved in one patient (though twice monthly 
tension headaches persisted). Overall, there was a reduction in 
MH frequency from a median of 1.5 before closure to 0.33 attacks 
per month after closure.
Preexisting Migraine Change after Percutaneous 
ASD Closure: Retrospective Studies
Wilmshurst et al. (19) reported change in preexisting MH in 21/71 
patients (30%) after closure. A group taking ASA and clopidogrel, 
a group that included eight change in preexisting MH patients 
(and three de novo MH patients), had significantly fewer MA 
attacks (or just incidents of aura) compared to those taking just 
ASA (p <  0.001). Episodes of MH were noted as particularly 
more frequent and severe in three patients taking ASA alone. 
Inhibition of migraine and aura events by addition of clopidogrel 
led the authors to theorize a role for platelet aggregation in the 
pathogenesis of migraine. Kedhi and Vermeerch (60) reported a 
drastic level of reduction in MH frequency and severity among 14 
patients who underwent pASDC. A Starflex™ occluder was used 
and it has much lower nickel (nitinol) composition proportion 
than the Amplatzer™ device. The authors speculated improved 
rather than exacerbated MH status could have stemmed from 
absence of a device-triggered nickel alloy allergic response [In a 
FiGURe 2 | The y-axes reflect patient count of migraine headache (MH) status change after pASDC; the numbers in the x-axes represent the study 
that corresponds to a given bar, and the studies that correspond to the x-axes numbers are listed sequentially in Table 2. Left side graphs:  
(A) preexisting MH change patient count within 7 days from closure; (C) cumulative preexisting MH change patient count by final follow-up; Right side graphs:  
(b) de novo MH patient count within 7 days from closure; (D) cumulative de novo MH by final follow-up. CHG, change.
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similar vein, Wertman et al. (64) reported evidence of nickel alloy 
allergic response associated with MH status change after pASDC.] 
Mortelmans et  al. (61) reported change in preexisting MH in 
22/75 patients (29.3%): there was an increase in MA prevalence 
from 8/75 (11%) before pASDC to 11/75 (15%) after closure, 
but a decrease in MO from 14/75 (19%) before closure to 9/75 
(12%) after; MH resolved in 12 patients at least 6 months after 
pASDC. With respect to the 10 patients in whom MH persisted, 
frequency was significantly reduced (p = 0.01). In addition, while 
all patients were adults, MH change occurred in preexisting MH 
patients who were significantly younger than pASDC patients 
not experiencing MH (p = 0.001), and MH change occurred in 
preexisting MH patients who had larger occluder devices than 
pASDC patients not experiencing MH (p =  0.004). Voet et  al. 
(81), in a follow-up (mean 52 ± 13 months) of the Mortelmans 
et al. study, reported MH cessation in an additional six patients 
(p  =  0.031), meaning an approximate reduction in collective 
persistent MH patient count from 23/75 (30.7%) before closure 
(Voet el al reported an additional patient with prior MH) to a 
post closure late follow-up rate of 16/71 (22.5%). Azarbal et al. 
(59) reported 7/23 (30.4%) patients with a history of MH; after 
pASDC, change in preexisting MH occurred in 4/23 (17.4%) 
patients. Resolution of MH occurred in 3/7 patients (42.9%) (all 
MA patients) and improved in the single MO patient. The overall 
changes (which merged ASD and patent foramen ovale patient 
outcomes) indicated significant levels of MH frequency reduction 
(p = 0.004) and severity reduction (p < 0.001). The MIDAS scale 
was used (IHS criteria were not referenced), and MH changes 
were noted within a 12-month mean follow-up period. Sharifi 
et  al. (63) reported change in preexisting MH in 5/13 patients 
(38%) within 40 h post pASDC; MH was characterized as sub-
stantially more severe relative to baseline attacks. The attacks (not 
responsive to ASA, ibuprofen or sumatriptan) were resolved in 
4/5 patients (80%) and much improved in the remaining patient 
within minutes (15 ±  8) of administration of clopidogrel. At 
9-month follow-up there was no further occurrence of migraine. 
Wertman et  al. (64) reported 5/42 patients (12%) experienced 
either change in preexisting MH (characterized as exacerbation) 
or de novo MH after closure. A nickel allergy test, completed in 
6 of 42 patients, revealed a positive result in 4/6 (67%), and there 
was a significant association (p = 0.035) between migraine status 
change (de novo MH or change from MH baseline) and positive 
nickel allergy response. The authors theorized that an inflamma-
tory response from an allergic reaction to nickel (a constituent 
of the Amplatzer™ occluder) could induce heightened platelet 
aggregation and embolism with consequent microinfarcts trig-
gering MH. Migraine was reduced or resolved by clopidogrel, 
and MH prevalence paralleled administration and withdrawal of 
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clopidogrel in a CDR pattern. Migraine was not assessed using 
IHS criteria, but the MIDAS questionnaire was adopted. The 
Knepp et al. (52) long-term study (median follow-up 73 months) 
investigating the safety and efficacy of pASDC using Amplatzer™ 
occluder in pediatric and adult patients reported cessation of 
preexisting MH in 2 of two patients within the follow-up period. 
Kato et al. (76) reported change in preexisting MH after pASDC 
in 18/20 patients (79%). Within 3  months post procedure, 
and relative to prior migraine, MH was exacerbated in 11 but 
improved in 7 patients, which included 1 patient whose MO 
transformed to MA. Migraine subsequently disappeared in 5/7 
patients in the improved group within 3 months from pASDC. 
Within 12 months from pASDC, 7/11 (63.6%) of the exacerbated 
group improved and MH resolved completely in 1 patient.
De Novo Migraine Prevalence after Percutaneous 
ASD Closure: Case Studies
Adult patients were involved in three of the five case studies 
reporting de novo MH after pASDC (57, 73, 75), and pediatric 
patients were involved in the remaining two studies (78, 92). All 
de novo case study MH events occurred within 7 days of closure 
and were type MA. Imaging results within follow-up after closure, 
including TTE or TEE, were normal (no evidence of embolization 
or thrombus). One patient’s MRI indicated minor periventricular 
hyperintensities (73). None of the studies Indicated abnormal 
platelet activity and the ASD shunts were resolved within follow-
up. In four of the case studies (57, 73, 78, 92) antithrombotics 
ameliorated, reduced, or abolished MA events; in one study, the 
thienopyridine appeared ineffectual (75). In three studies, MH 
disappeared at 4 months (92), 6 months (57), and at 9 months (75). 
However, although MH disappeared in one of the patients, aura 
without headache persisted at 2-year follow-up (75). In the other 
two studies MH events continued at 7-year (73) and 2-year (78) 
follow-up times. Modulation of MH symptom disappearance and 
re-appearance was most pronounced in one study in particular; 
there was exquisite response to thienopyridine administration 
(ticlopidine) and withdrawal in a CDR pattern (73).
De Novo Migraine Prevalence after Percutaneous 
ASD Closure: Prospective Studies
De novo MH following pASDC was reported in two of three 
prospective studies (71, 72). Luermans et al. (71) reported de novo 
MH in 4/63 patients (6%) after the procedure. In the overall study 
result, which included outcome for 23 patients with preexisting 
MH (see Preexisting MH Change after Percutaneous ASD Closure: 
Prospective Studies), there was a significant reduction in MH at 
12-month follow-up (p = 0.003). Wei et al. (72), reported de novo 
MH after closure in 24/40 patients (60%); 18 patients had the first 
MH within 30 days and the other 6 within 12 months after the 
procedure (median: 30  days). Consistent with greater occluder 
size reported in de novo MH patients by Mortelmans et al. (61), 
Wei et al. reported that those experiencing de novo MH had larger 
ASD size (p = 0.01) and a greater ASD to occluder length ratio 
(p = 0.03). Of 17 patients whose plasma CGRP was tested before 
and after closure, 4/17 (24%) experiencing de novo MH had lower 
pre-closure compared to post closure CGRP levels (p = 0.042). 
There was also indication that the CGRP levels increased during 
MH attack (p = 0.03). Authors postulated that larger ASD size and 
lower pre-closure CGRP could be predictors of de novo MH after 
pASDC. MH remitted spontaneously in 7/24 (29%) of de novo 
MH patients within 6 months of pASDC, but persisted in 17/24 
(71%). It was noted that one patient’s MH attacks responded most 
favorably when ASA was replaced by clopidogrel.
De Novo Migraine Prevalence after ASD Closure: 
Retrospective Studies
De novo MH was reported in 10 of 13 retrospective studies (19, 
46, 51, 52, 58, 61, 64, 67, 76, 93). Yew and Wilson (58) reported 
de novo MH in 2/25 (8%) patients after closure; symptoms were 
strongly suggestive of MA (IHS MH criteria were not referenced) 
and interpreted in this review as MA. Pediatric and adult patients 
were included in the study, and de novo MH (categorized as MA 
in this review) occurred within 1 week after closure in one of the 
de novo MH patients. At final follow-up (60 months) MH epi-
sodes continued to occur in one patient but were resolved in the 
other patient. Wilmshurst et al. (19) reported de novo MH in 9/71 
adult patients (13%) after closure. As mentioned in the change in 
preexisting MH section, the group taking ASA and clopidogrel 
(a group that included three de novo MH and eight patients with 
preexisting MH change) had fewer MA attacks (or just incidents 
of aura) compared to those taking just ASA (p < 0.001). Episodes 
of MH were noted as particularly more frequent and severe in two 
de novo patients taking ASA alone. As also noted in the section for 
retrospective preexisting MH change, the inhibition of migraine 
and aura events by addition of clopidogrel led the authors to 
postulate a role for platelet aggregation in the pathogenesis 
of migraine. Mortelmans et  al. (61), at 2 months post pASDC, 
reported de novo MH in 9/75 patients (12%); MA occurred in 
seven and M0 in two patients. At 6 months after pASDC, de novo 
MH was reported in 10/75 patients (13%); MA in seven; and MO 
in three patients. De novo MH patients were significantly younger 
(29 ± 18 vs. 58 ± 17) than pASDC patients not experiencing MH 
(p = 0.045), and de novo MH patients had larger occluder devices 
than pASDC patients not experiencing MH (p = 0.01). Voet et al. 
(81), in a follow-up (mean 52 ± 13 months) of the Mortelmans 
et al. study, reported MH cessation in six de novo MH patients 
(p = 0.03); this study also reported cessation in six patients with 
preexisting MH. As previously noted (see Preexisting Migraine 
Change Retrospective Studies) Wertman et al. (64) reported 5/42 
patients (12%) experienced either change in preexisting MH 
(characterized as exacerbation) or de novo MH after closure (de 
novo vs. prior MH outcomes were not distinguished, and were 
reported in Table 2 conservatively as two patients with change in 
preexisting MH and two with de novo MH). Additional highlights 
of this study are outlined in the preexisting MH section reviewing 
retrospective studies. Providencia et al. (94) reported de novo MH 
in 3/25 patients (12%), each of whom had a morphological trait 
(short aortic rim) that significantly differed from other patients 
not experiencing MH after closure (p = 0.036). Migraine resolved 
in 2/3 patients (67%) within 12 months. Rodés-Cabau et al. (46) 
reported de novo MH in 13/112 patients (12%) after pASDC. 
Inception of de novo MH occurred in 6/13 patients (46%) within 
7 days of pASDC; MA occurred in five of these patients and MO 
in one patient. While MH spontaneously disappeared in 4/13 de 
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novo MH patients (31%), it continued in 9/13 (69%) at 2 years 
post pASDC, though frequency of MH had significantly reduced 
relative to frequency at the 3-month follow-up (p = 0.032). The 
author’s speculated that, for some patients, pASDC may act 
as permanent MH trigger. Pediatric and adult patients were 
included (age range 16–60; mean 39 ± 19). Patients developing 
MH were significantly younger (p = 0.02), tended to be female, 
and pASDC was the sole independent predictor of MH (odds 
ratio 7.7; p =  0.01). The emphasis in three studies (51, 52, 93) 
was assessment of pASDC safety and efficacy; MH status was also 
reported. Li et al. (93) investigated the safety and efficacy of TTE 
(as opposed to TEE) guided pASDC. Reporting a 96.9% rate of 
successful TEE-guided closure, de novo MH occurred in 3/188 
patients (2%) after closure, 2/3 (67%) of which occurred within 
7 days of pASDC; IHS criteria were not referenced. Pediatric and 
adult patients were included, and pASDC patients were divided 
in to three groups based on ASD diameters (5–14 mm, n = 66; 
15–20 mm, n = 60; and 21–38 mm, n = 65). Two of the de novo 
MH patients where from the group with the largest ASD diameter, 
the other de novo MH patient was from the group with an ASD 
diameter in the 15–20  mm range. Migraine events resolved in 
all three patients within follow-up. Complications were reported 
within the group with the largest occluder devices (these patients 
were not specified as experiencing de novo MH): devices in three 
patients migrated and required cardiac surgery; one patient 
developed a device thrombus that resolved over 10 days of inten-
sified anticoagulant administration. Knepp et al. (52), in a long-
term study (median follow-up 73  months; 60% response rate) 
investigating the safety and efficacy of pASDC using Amplatzer 
occluder in pediatric and adult patients, reported de novo MH in 
4/94 of patients (4%) after pASDC. Resolution of the four cases 
of de novo MH was not specified; non-resolution was assumed 
(persistent MH cessation was also reported in two patients with a 
prior history of MH as noted in the preexisting MH retrospective 
section). While there was a 97% rate of successful ASD closure, 
one child died of a cerebral vascular accident at 18 months post 
closure. Vijarnsorn et al. (51) also reported long-term outcomes 
(12 months after closure) following pASDC with the Amplatzer 
occluder. Patients were divided into pediatric, adult, and older 
adults groups. De novo MH occurred in 19/353 of patients (5%) 
within 12  months of closure; de novo MH prevalence did not 
significantly differ between groups and ranged from 4 to 8.3% 
across all 3 age groups. There was a 93.4% rate of ASD closure, 
no mortalities, but greater atrial fibrillation/flutter as well as chest 
discomfort in older adults at 12 months after closure (p < 0.05). A 
single incident of eye embolism, which resolved within 3 months 
post procedure, was also reported. In the largest study to date 
focusing on the potential impact on migraine of pASDC, Kato 
et al. (76) reported de novo MH in 23/207 patients (11%) after 
closure (13 MA; 10 MO). Pediatric and adult patients were 
included in the study, and compared to the age of pASDC patients 
who did not experience post closure MH (M = 27 ± 22), de novo 
MH patients were significantly younger (M = 15 ± 11; p = 0.03). 
Within 7 days from pASDC, 13/23 (57%) de novo MH incidents 
occurred and of these 10 were MA and 3 MO. Administration of 
thienopyridines (ticlopidine or clopidogrel) improved (reduced 
frequency) MH in 6/23 patients (26%). At final follow-up 
(45 ± 23 months), de novo MH resolved in 8/23 patients (35%), 
improved in 14/23 patients (61%), but nevertheless continued at 
final follow-up in 15/23 patients (65%); a pattern consistent with 
other research (46, 58, 61, 73, 78). Speculating in parallel with 
other research (46), it was suggested that occluder implantation 
could act as a permanent MH trigger. Post closure replacement of 
ASA with either ticlopidine or clopidogrel reduced MH frequency 
and aborted continuous MH events.
De Novo Migraine Prevalence after ASD Closure: 
Randomized Controlled Trial
In the first randomized controlled trial Rodes-Cabau et al. (79) 
investigated the efficacy of clopidogrel to prevent de novo migraine 
after pASDC. Patients (n = 171) with no history of migraine were 
randomized to one of two groups: ASA plus a placebo (n = 87; 
the control group) or ASA plus clopidogrel (n = 84; the clopi-
dogrel group). De novo MH occurred in 27/171 patients (16%) 
within 3 months following the procedure (14 MA; 13 MO); de 
novo MH occurred in 16/27 patients (59%) within the first week 
after pASDC. The ASA plus clopidogrel group had significantly 
fewer de novo MH incidents (p = 0.03) and a significantly lower 
MIDAS scale severity rating (p = 0.046). Of 155 patients adherent 
to antithrombotic treatment (control group n = 79; clopidogrel 
group n = 76), incidence of MH attack within 3 months was 19/79 
in controls (24.1%) compared to 7/76 in the ASA plus clopidogrel 
group (9.2%)—an approximately 15% significant (p  =  0.02) 
reduction of migraine incidents. In addition, within the 3 months 
after pASDC the clopidogrel group had less than half the number 
of MH days compared to the control group (p = 0.02).
DiSCUSSiON
This review encompassed 25 studies and 1,646 patients who 
underwent pASDC between May 2003 and November 2015 and 
investigated the number of patients experiencing MH status 
change subsequent to pASDC. Because of a difference in preva-
lence, publishing bias, or both, de novo MH data were reported 
in more studies (18/25) more comprehensively than change in 
preexisting MH (12/25 studies). For example and as noted in 
Section “Results,” a breakdown of change after implantation in 
preexisting MH differentiated by either by gender or MH type 
was not available, though additional categorical breakdown by 
gender and type was available for 52 and 80% of de novo MH 
patients, respectively.
As a prelude to discussion of the results and as noted in the 
introduction, this review focuses on MH status change, change in 
preexiting MH or the rise of de novo MH, within the context of a 
reparative coronary procedure, pASDC. Because of this context, 
caution should be exercised in generalizing findings and the 
implications thereof to migraine pathophysiology in the general 
population.
After pASDC and by final follow-up, MH changed (most 
often in frequency or severity) in 72% of patients (91/126) with 
a history of preexisting MH, and more strikingly debuted in 
between 10 (153/1,520) and 18% (153/836) of patients with no 
prior history of MH. The overarching finding was the modula-
tion of migraine status evident in a substantial proportion of 
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patients (see Table 1 for a summary) within hours to months after 
implantation. The increase and decrease of migraine incidence 
appeared in step with initial heightened proinflammatory but 
months later reduced inflammatory stages of endothelialization. 
The most apparent modulators were the procedure itself and 
antithrombotic administration, each of which was often tempo-
rally juxtaposed to MH status change. The temporal link to the 
procedure was underlined by the relatively high percentage of de 
novo MH occurrence within the 7-day post procedure interval 
(34%); the temporal link to antiplatelet agents was evident in the 
rapid modulation of migraine associated with administration in 
11/25 studies.
MH Status Change: Timing and Type  
of MH
The count of patients experiencing MH status change was 
obtained for two time points: the interval within 7  days after 
implantation and at final follow-up, the latter ranged from 3 to 
73 months (Mdn = 12). The substantial impact of the procedure 
itself was underlined by the early post implantation change in 
MH status. While more than a few studies (63, 65, 69, 70, 75, 77, 
78, 80) reported MH change within hours of the procedure, by 
7 days after implantation 12% (11/91) of patients with preexisting 
MH underwent MH change (mainly in frequency or severity), 
and the initial onset of de novo MH occurred in 34% (52/153) 
of de novo cases. While type of MH was not differentiated in 
20% of de novo MH patients (31/153), data that were available 
indicated de novo MA within 7  days from pASDC accounted 
for MH debut in 48% of de novo MH cases (25/52) and de novo 
MO within 7 days from implantation accounted for MH debut 
in 12% of patients (6/52). Relative to the 33% prevalence of MA 
in the general population (95), by final follow-up the rate of total 
de novo MA patients after pASDC was high, at 58% (71/122); 
the rate of MO was 42% (51/122). Even in the unlikely event 
that undifferentiated MH in all de novo patients fell in the MO 
category there would be 54% MO (82/153) and 46% MA (71/153) 
and hence still a disproportionately large percentage of MA 
relative to the general population prevalence. By final follow-up, 
change in preexisting MH occurred in 72% of patients (91/126), 
and de novo MH occurred in 10–18% of patients with no history 
of MH. Also within follow-up, there was improvement in 14% 
of patients with preexisting MH and resolution in 37% (47/126) 
of those with preexisting MH. With respect to de novo MH, 
MH in 10% of patients (16/153) improved and in 24% (37/153) 
MH resolved. Improvement or resolution occurred in 52% of 
patients (65/126) with a prior history of MH within follow-up, 
but nevertheless in 63% of patients (79/126) with a prior history 
of MH, episodes continued beyond follow-up. Improvement or 
resolution occurred in 35% de novo MH patients (53/153) within 
follow-up, but in 76% who experienced de novo MH (116/153) 
migraine continued beyond follow-up.
MH Status Change and Antiplatelet 
Agents
Effective modulation of MH status by antiplatelet agents, was 
expressly reported in 11/25 or 44% of studies (see Results). 
ASA was used in 21/25 (84%) studies, and the thienopyridine 
clopidogrel was used in conjunction with ASA in 12/25 (48%) 
of studies. Two studies, including a RCT, indicated significantly 
reduced MH frequency in those taking dual antiplatelet therapy 
(ASA plus clopidogrel) relative to ASA alone (19, 79). In addition, 
some data indicated an exquisite MH response in CDR fashion to 
antiplatelet agents (64, 70, 73).
Relevance of Gender, Defect Size, and Age
As reported in Section “Results,” patient counts of change after 
pASDC in preexisting MH differentiated by gender (as well as 
MH type) was not available from the literature, and de novo MH 
incidence differentiated by gender was available for just 52% of 
new-onset cases. The available data indicated 80% of de novo MH 
occurred in females and 20% in males, with MH debut by gender 
not specified in 48% of de novo MH patients, though it is likely 
most de novo MH cases not differentiated by gender were female 
patients given the disproportionately high female to male ratio of 
pASDC patients. Why ASD are more common in females than 
males (53) is unknown, but higher incidence of MH in females 
(see the introduction) than males may be related to sex-linked 
differences in platelet reactivity. Platelets have demonstrated 
greater reactivity in women than men in response to adenosine 
diphosphate (96, 97), which is a known proinflammatory sub-
stance that would normally be released in higher concentrations 
during the pASDC procedure and during the subsequent period 
of endothelialization. Platelet reactivity is likely influenced by 
hormones (particularly estrogen fluctuation in women associated 
with menstruation, the postpartum period, hormone replace-
ment therapy, and menopause), but the actual role of hormones 
in platelet biology remains undecided (98).
Three studies reported anatomical traits, which may have 
predisposed patients to de novo MH or exacerbated preexisting 
MH. One study reported short aortic rim in de novo MH patients 
(68); another study reported significantly greater ASD/occluder 
size in both patients with preexisting MH change and in de novo 
MH patients (61); an additional study reported significantly 
larger ASD size and ASD length to occluder length ratio in de 
novo MH patients (72). Otherwise, clinical characteristics (e.g., 
Qp/Qs, ASD size, occluder size, etc.) did not differ significantly 
between those who did and those who did not experience pASDC 
migraine status change.
Occurrence of de novo MH has been reported to not differ 
significantly between pediatric and adult patients (51), though, 
contrarily, other research reports higher de novo MH prevalence 
among pediatric patients (46, 77) and younger adult patients 
(46, 61). Some data indicated adults who underwent change in 
preexisting MH were younger that those in whom MH did not 
persist or develop (61).
Potential Mechanisms
Differing theories have been advanced regarding the nature of 
pathophysiological change and migraine following pASDC and 
posited mechanisms can be differentiated into microembolic, 
biochemical, and allergic response categories, though migraine 
status change in the context of pASDC likely involves interactions 
among such potential agents.
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Microembolism
The known association between cardiovascular risk factors (e.g., 
pre-clinical brain lesions and ischemic stroke) and MA is well 
documented [Elliott (99); Kruit et al. (36); Kurth et al. (38); Kruit 
et al. (35); Schurks et al. (39); Bigal et al. (34); Kruit et al. (37)]. 
Several other vascular risk factors have been reported as associ-
ated with migraine: experimental hypoxia (100); altered brachial 
and femoral artery compliance as well as decreased brachial 
artery diameter (41); increased carotid artery media thickness, 
a subclinical marker of early atherosclerosis (43, 44), has been 
reported as heightened in pediatric migraineurs (45) and adult 
migraineurs (42). Migraineurs (particularly women) with MA 
have two times the risk of ischemic stroke (38), and MA and 
migraine in general, in an unadjusted population-based analysis, 
have been associated with stroke, myocardial infarction and 
claudication (34). The implication is that inflammatory response, 
related to vascular conditions, is a potential trigger of SD, at least 
as concerns MA.
The current review data showed a disproportionately high 
percentage of MA among patients experiencing de novo MH but 
evidence of device thrombus was rare, just two incidents in 1,646 
patients (52, 93). In research not focusing on MH, the largest 
study assessing device thrombus formation after ASD percutane-
ous closure (101) found thrombus formation occurred in 1.2% 
(5/407) of ASD patients, which is a low rate but nevertheless 
about 10 times higher than that in the current review. However, 
the latter study assessed thrombus formation for six occluder 
device types including the Amplatzer™ device; the Amplatzer™ 
device actually had a 0% incident rate of device thrombus forma-
tion and the other device types accounted for the 1.2% incidence 
of device thrombus formation. The Amplatzer™ device was used 
in more than 95% of patients in the current review so the 0% 
rate of device thrombus evidence with respect to the Amplatzer™ 
occluder reported by Krumsdorf et al. is quite consistent with the 
very low incidence of device thrombus reported in the present 
review. Moreover, in the current review, the presence of lesion 
was evident in only one patient (62); and there was no evidence 
of abnormal platelet activity reported—observations that do not 
favor an ischemic-related trigger theory of MA.
However, as noted in the introduction, research in mice 
has demonstrated subclinical microembolism triggers SD, the 
substrate of MA. Air bubble or particles (micro-spheres) were 
introduced into the carotid circulation; but these microemboli did 
not result in tissue infarction, did not leave histological evidence 
of tissue damage or inflammation response (17). Microembolic 
theories of migraine are not new but do appear to be gaining grow-
ing favor (102, 103). Moreover, in another type of ASD known as 
a patient foramen ovale (PFO), venous matter unfiltered by the 
lungs can access left side of the heart (and hence the brain) via an 
aberrant conduit that forms a right-to-left interatrial shunt. An 
ASD has the opposite left-to-right shunt property except during 
instances where right atrial pressure exceeds the left [such as 
during a sneeze or Valsalva maneuver]. PFO is unambiguously 
linked to cryptogenic stroke (104), injected microbubbles can 
trigger MA in patients with symptomatic PFO (105, 106), and 
MA has been triggered with high consistency by injection of scle-
rosing agents, which induce an inflammation response, in those 
with a PFO (107, 108). Just as the RLS mechanism of PFO can 
introduce potential subclinical microembolic and inflammatory 
substances into the left side of the heart, the pASDC procedure 
and subsequent endothelialization induces potential subclinical 
microembolic and proinflammatory elements on the left side of 
the occluder that have access to the brain.
Allergic Response
The amount of nickel titanium (nitinol) in a given brand of occluder 
device may vary but it is nevertheless a common denominator in 
most occluder devices (109). While reported incidence of nickel 
allergic response related to implanted occluders is rare, a 5-year 
study involving 131 PFO patients found post implantation chest 
discomfort (and palpitations) was significantly greater in those 
with nickel hypersensitivity (110). In a patient with confirmed 
general metal hypersensitivity, extreme exanthema 3 days after 
percutaneous PFO closure necessitated explantation of the 
implanted device, and 3  days after device removal skin lesions 
resolved (111). A case of severe contact dermatitis erupting the 
day after percutaneous closure of a patent ductus arteriosus has 
been described in a patient with a confirmed nickel allergic 
response; several days subsequently, the dermatitis disappeared 
after the administration of prednisone (112). Only one study in 
the current review reported evidence of a significant association 
between migraine status change and a positive nickel allergy 
response in 67% (4/6) patients (64).
biochemical Constituents and Platelets
The apparent absence of abnormal platelet dynamics in the data 
for this review likely reflects the efficacy of antiplatelet agents. 
Some research involving PFO (RLS) and MH has shown reduc-
tion or resolution of MH, mostly MA, using clopidogrel (113), but 
a randomized control pilot project reported that clopidogrel had 
no favorable effect on MH (114). The sole pASDC RCT in the cur-
rent review reported the addition of clopidogrel was associated 
with a greater than 50% reduction in the burden of MH days as 
well as a significant reduction in MH incidents (79).
As already noted, 11/25 studies in this review expressly reported 
the favorable response of MH to antiplatelet agents. Platelets 
contribute to the generation of microembolism (115, 116) and 
heightened aggregation of platelets has been demonstrated in 
migraineurs (117) and after pASDC (118). Aggregating platelets 
normally release a number a substances including thromboxane 
A2, adenosine diphosphate and serotonin. In addition, serotonin 
released from aggregating platelets serves as a vasoconstrictor, 
but under normal conditions, and as aggregation subsides, 
reduced levels of serotonin can lead to vasodilation (119). It 
has been hypothesized that alteration in plasma serotonin level 
causes MH (MO or MA), and that platelet aggregation and 
heightened serotonin induce vasoconstriction causing reduction 
in blood flow and the neuronal manifestation of aura (14). Other 
research, already cited, argues that pro-inflammatory factors 
(including platelet aggregation and serotonin) may trigger the 
neuronal manifestation of MA (17, 102), which is SD. It follows 
that subclinical microembolism, derived from a proinflammatory 
cascade including platelet aggregation, plays a role in MH status 
change after pASDC. Also associated with migraine episodes are 
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up-regulated inflammatory platelet and white blood cell (leuko-
cyte) aggregates as well as cytokines (e.g., interleukins 1, 6, and 8 
and tumor necrosis factor-α); altered nitric oxide concentrations 
have also been found during MH attacks (15). In addition, and 
as mentioned in the introduction, elevated plasma endothelin 
(ET-1), a marker for endothelial injury, was recently reported in 
those with migraine (42).
Sumatriptan, the serotonin (5-TH) receptor agonist, has been 
presumed to relieve MH pain by interfering with 5-HT recep-
tors on trigeminal nerve endings (120). The neuropeptide and 
potent vasodilator CGRP is also influenced by administration of 
sumatriptan: CGRP levels are reduced and migraine pain can be 
effectively subdued (121). As noted in the introduction, antitheti-
cally, migraine pain can be induced by intravenous introduction 
of CGRP (30). The capacity of CGRP’s level to alter migraine pain 
argues for its role as a mechanism in the trigeminovascular noci-
ceptive pathway. One study within the current review reported 
24% of patients (4/17) with de novo MH had significantly lower 
pre-closure relative to post-closure CGRP levels, Wei et al. (72). 
Treatment with sumatriptan was not reported. Moreover, post 
closure CGRP and treatment with triptans was scarcely reported 
across all studies. In preexisting MH patients CGRP levels were 
not reported and triptans were administered to few patients 
(7/1,646). With respect to de novo MH patients, and with the 
exception of the Wei et  al. study, CGRP measurement was not 
reported and administration of triptans was reported for only a 
few patients (3/1,646). Considering that this review assessed inci-
dence of migraine status change within the bounds of pASDC, 
and the primary procedure-related adverse outcome concern is 
thromboembolism, it should be expected that antithrombotic 
and antiplatelet agents constitute the main prophylaxis measure. 
However, given the potential inhibitory effect of CGRP antago-
nists on SD (22), and this neuropeptide’s apparent integral role in 
migraine pain management, recent advances in CGRP antagonist 
research and development (33) auger well for the future contribu-
tion of CGRP antagonists in the treatment of migraine, both in 
general population and potentially for management of migraine 
pain within the context of migraine after pASDC.
endothelialization: A 3-Month Process?
The overall pattern of MH early intensification followed by 
later amelioration seems to roughly parallel stages of early 
implantation and progressing endothelialization. The initial 
post procedure intensification of MH might be the expected 
outcome of the inflammation response to the trauma of occluder 
implantation with heightened early proliferation of platelets and 
other proinflammatory potential thromboembolic elements. 
The 34% rate of patients with de novo MH constrained within 
hours to 7  days from pASDC seems to exemplify early post 
procedure intensification of MH status change. After days, weeks 
and months of device endothelialization, reduced inflammation 
response would be expected as the healing process progresses. 
The estimated time to complete endothelialization as derived 
from animal (swine) research is 3 months (122), and it could be 
assumed that proinflammatory substances and microembolism 
related to endothelialization are therefore an unlikely cause of MH 
after this length of time. However, it has been demonstrated that 
complications from late, incomplete endothelialization can occur 
including coronary and cerebral embolism at 5 and 8 years after 
device implantation (123, 124). Accordingly, proinflammatory 
derivatives of incomplete endothelialization may be the trigger of 
MH events persisting beyond the previously estimated 3-month 
completion time of endothelialization. In the current review, this 
may underlie the high percentages of patients with MH persisting 
after final follow-up: 63% of preexisting MH cases and 76% of de 
novo MH cases. In five patients, MH persisted 2 years (78), 5 years 
(58), and 7 years (73) after pASDC.
Evidence of complications associated with incomplete 
endothelialization are rare but have been reported (124, 125). 
In a study of patients requiring explantation of percutaneous 
implants all showed so called neo-endothelialization, and 56% 
of the patients (5/9) had recurrent thromboembolic events prior 
to explantation; 2 of the 5 had recurrent coronary and cerebral 
embolism prior to explantation (124). An improvement in device 
technology that would minimize the need for explantation, at 
least where proinflammatory reaction stems from metal allergic 
response, would be the development of biodegradable devices, 
though such devices have not yet been formally approved (109).
The development of de novo MH is obviously a negative and 
undesirable side effect associated with pASDC, which underlines 
the need for continued scrutiny of procedure associated vari-
ables. The potential occurrence of de novo MH in this context, 
which ranged between 10 and 18% in the current review, should 
be weighed against overall prognosis of MH after pASDC and 
of course the success rate of closure. In 19/25 or 76% of studies 
(and in most patients) resolution, improvement or indications for 
momentum in the direction of MH improvement was indicated 
within follow-up and the frequency and severity of both de novo 
and preexisting MH tended to diminish gradually approaching 
final follow-up from an early post pASDC peak (46, 52, 57–59, 
61–65, 68, 70–72, 75, 77, 82, 85, 93). In addition, high rates of 
successful ASD closure (a 93% rate estimated across the data) 
and very low complication rates but rapid recovery have become 
earmarks distinguishing pASDC. Considering just known com-
plication rates (combined major and minor), the surgical method 
of ASD closure has a complication rate of approximately 44% 
compared to 6.9% for the percutaneous method (126).
Yet, the high rate of persistence of MH beyond follow-up, 
particularly conspicuous in de novo occurrences, is an obvious 
drawback of pASDC. While isolating the cause of de novo MH 
in the context of post pASDC and accounting for MH perpetu-
ation after a median 12 months (range 3–73 months) follow-up 
is beyond the scope of this review, a proinflammatory trigger 
is suggested by three main findings. First, research has dem-
onstrated an association of MA with ischemic stroke and with 
proinflammatory elements including subclinical microembolism 
(see subsections Microembolism and Biochemical constituents and 
platelets). In the data reviewed, MA emerged as the dominant 
type of de novo MH. Second, and as already noted, research has 
found higher aggregation of platelets in migraineurs (117) and 
after pASDC (118). The relatively high efficacy of antiplatelet 
agents expressly reported in 11/25 studies reviewed argues for a 
role of platelets (platelet aggregation, platelet-leukocyte aggrega-
tion, platelet serotonin secretion, etc.) in migraine and for the 
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validity of antiplatelet agents as a migraine prophylaxis. Third, 
and perhaps most significantly was the timing of MH status 
change: the wax and wane of MH loosely paralleled early post 
procedure intensified (heart tissue) inflammatory response and 
the subsequently diminished inflammatory response occurring 
at final follow-up, the latter ostensibly associated with advanced 
endothelialization.
While further studies are needed to determine the optimal 
duration for antiplatelet administration, the persistence of de 
novo MH in a large proportion of patients beyond final follow-up 
evident in the data suggests an extended period of antiplatelet 
agent use following pASDC is warranted. In addition, because 
antiplatelet agents are generally not without some negative side 
effects (such as increased bleeding), for non-acute, longer-term 
application consideration should be given to use of alternative 
non-standard antiplatelet agents (e.g., nattokinase) that may have 
lesser side effects yet potentially prove sufficiently effective. While 
assessment of efficacy of such alternative stream antithrombotic 
agents is outside the extent of this review, one indicator will be 
the outcome of a clinical trial currently underway for nattokinase 
(https://clinicaltrials.gov/ct2/show/NCT02080520).
Limitations
The main limitation of this review was reliance on frequency 
qualitative data, which is a restrictive and unsophisticated meas-
ure. While some quantitative data was available, such data was 
either too scarce or inappropriate to measure patient prevalence 
of change in MH status after pASDC. Other limitations include 
a possible MH incident recall bias given 13/25 studies were ret-
rospective, some inconsistency in use of IHS (56, 127) diagnostic 
criteria (17/25 studies used IHS criteria), and the virtual absence 
of testing for resistance to the most used theophylline clopidogrel. 
A positive test for resistance could result in an under estimate 
of this antiplatelet agent effectiveness. It also warrants mention 
that inconsistency in use of IHS criteria by medical or research 
personnel without neurological expertise could have resulted in 
misdiagnoses of migraine, the extent of which can not be deter-
mined from the data.
CONCLUSiON
The studies reviewed revealed change in MH—a neurological 
event—following a vascular corrective procedure. Between 
10 and 18% of patients experienced de novo MH and 72% of 
patients with preexisting MH experienced a change in MH 
status after pASDC. In 19/25 studies intensification of change in 
MH status in the initial, hours, weeks and months after pASDC 
was followed by amelioration of MH as the post operative 
timeframe approached 6–12  months; a pattern that seems to 
loosely parallel stages of endothelialization: early heightened 
proinflammatory response and the reduction of the latter in later 
near-completion stages of endothelialization. This lends further 
support to the contention that proinflammatory response 
factors (including, aggregated platelets, serotonin, ADP and 
microembolism) trigger MH status change after pASDC. This 
contention is additionally reinforced by effective MH treatment 
by antiplatelet agents expressly reported in 11/25 studies, and 
by the emergence of MA as the dominant de novo MH type, 
its known association with ischemic stroke also implicating 
proinflammatory possibly microembolic, undetected, triggers 
of MH. Despite general indications for gradual MH ameliora-
tion, there were high rates of MH persistence, particularly de 
novo MH, beyond the 12-month median follow-up time. Other 
research cited has demonstrated incomplete endothelializa-
tion extending to several years after pASDC. Progressing but 
on-going endothelialization could explain MH amelioration at 
final-follow-up but nevertheless continued persistence beyond 
final follow-up.
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